Touchlight, a London, UK-based biotechnology company, received a grant from Bill & Melinda Gates Foundation.
The amount of the grant was not disclosed.
The funding builds on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses.
Led by CEO Karen Fallen, Touchlight is a company focused on the provision of DNA services and manufacture of enzymatically produced novel DNA formats, such as doggybone DNA (dbDNA) to enable the development of genetic medicines. Its DNA Services provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences.
As part of the grant, Touchlight will also be investigating the performance of doggybone DNA for therapeutic monoclonal antibody production.
FinSMEs
01/12/2022